Pages
-
-
Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status
-
-
External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer
-
-
CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1
-
-
Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival
-
-
Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile
-
-
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma
-
-
Establishment of the Dutch nationwide, interdisciplinary infrastructure and biobank for fundamental and translational ovarian cancer research
-
-
Establishment of the Dutch nationwide, interdisciplinary infrastructure and biobank for fundamental and translational ovarian cancer research
-
-
PD-1T TILs as a predictive biomarker for clinical benefit to PD-1 blockade in patients with advanced NSCLC
-
-
Prognostic value of stromal tumor-infiltrating lymphocytes in young, node-negative, triple-negative breast cancer patients who did not receive (neo)adjuvant systemic therapy
-
-
Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk
-
-
Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma
-
-
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer
-
-
Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ
-
-
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
-
-
Gene expression profiles of esophageal squamous cell cancers in Hodgkin lymphoma survivors versus sporadic cases
-
-
Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM)
-
-
Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses
-
-
Transcriptome-wide association study of breast cancer risk by estrogen-receptor status
-
-
Comprehensive analysis of cutaneous and uveal melanoma liver metastases
-
-
Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer
-
-
Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma
-
-
Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation (vol 5, 4999, 2014)
-
-
Body mass index and breast cancer survival: a Mendelian randomization analysis
Pages